Navigation Links
BD Announces Agreement to Acquire Carmel Pharma, Inc.
Date:7/27/2011

FRANKLIN LAKES, N.J., July 27, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it signed a definitive agreement to acquire Carmel Pharma, Inc., a Swedish company that manufactures the PhaSeal® System, the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.  The acquisition is expected to close by the end of BD's fiscal year 2011. The financial terms of the agreement were not disclosed.

The acquisition would expand the scope of BD's healthcare worker safety emphasis, especially in the area of parenteral medication delivery.

"We believe that the combination of Carmel Pharma's current sales presence in hospital pharmacy with BD's much broader institutional presence on healthcare safety can accelerate adoption of this key safety platform," said William A. Kozy, BD Executive Vice President.

The PhaSeal System minimizes the risk of exposure to potentially harmful liquids and vapors from toxic drugs. It is typically used by pharmacists, pharmacy techs, nurses and oncologists in inpatient, outpatient and medical practice settings for the preparation and administration of hazardous drugs such as those used in the treatment of cancer.  Studies continue to document healthcare worker exposure to hazardous drugs in the preparation and administration of hazardous drugs such as some chemotherapeutics used in the treatment of cancer.  

"Healthcare worker safety remains a major issue for global healthcare, and hazardous drug exposure is an issue needing better solutions.  As cancer drug therapy proliferates, this is a unique opportunity for BD to further expand its role in protecting healthcare workers," said Vincent A. Forlenza, BD President and Chief Operating Officer. "This planned acquisition aligns
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
2. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
3. Heska Announces 15% Revenue Growth, Fourth Consecutive Profitable Quarter, for the Second Quarter of 2011
4. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
5. Onyx Pharmaceuticals Announces Second Quarter 2011 Financial Results Teleconference and Webcast
6. SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
7. HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis
8. CAP Announces Advanced Digital Technology for 2012 Programs
9. Vapotherm Announces Commercial Launch of Flowrest® Homecare Device
10. Accuray Announces Proposed Offering of $75 Million Convertible Senior Notes
11. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... Scenario for Medical Devices in the US ...   Changing Regulatory and Reimbursement ... Market   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Botanic Pharmaceutical Inc. (NYSE AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... recently hosted a technical exchange between 13 senior research ... and herbal medicine. China Botanic participated ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3
(Date:5/21/2013)... 2013 Standard advice for mattress shoppers ... else. However given industry’s less than exceptional satisfaction ratings ... the internet, Consumer Mattress Reports sets out to revise ... Best Mattress .” , This article addresses several components ... that may not be readily apparent to many shoppers. ...
(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...
Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2
... International Liver Congress 2009, the 44th annual meeting of the ... Journalist registrations are being accepted for International Liver Congress 2009, ... , Press registration is free of charge for all holders ... The official EASL press conference will be held from 13.15 ...
... A failing heart makes a lot of a hormone needed ... but not enough of the enzyme needed to activate it, ... College of Georgia researchers found people in heart failure have ... pro-atrial natriuretic peptide, a hormone made by heart muscle cells ...
... WASHINGTON, March 31 Jeffrey Levi, Ph.D., ... today before the U.S. House Energy and Commerce Committee,s ... Care Work for American Families: Protecting the Public Health." ... investing in prevention, and the importance of incorporating public ...
... March 31 The not-for-profit LENA Foundation ... Biennial Meeting of the Society of Research in Child ... Colorado, four talks and one poster will be presented ... http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 )"This year,s SRCD is a great opportunity ...
... 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) ... Award" is a most coveted, prestigious award, and ... Science and Technological Development. Submitted with the award ... preliminary trial of their Ribavirin product, confirming its ...
... March 31 Five local organizations and,individuals committed ... cholesterol,in Hispanic communities were awarded 2009 Cheerios Angel ... Chosen from a winning pool of nominations, ... healthier lifestyles and provided excellent resources to help ...
Cached Medicine News:Health News:New tests provide new insight into why patients are in heart failure 2Health News:New tests provide new insight into why patients are in heart failure 3Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 2Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 3Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 4Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3Health News:Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 3Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 4
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Medicine Products: